A second failed efficacy trial of Medivation Inc./Pfizer Inc.’s Dimebon (latrepirdine) provided the final nail in the coffin for the once-promising Alzheimer’s disease treatment.
On Jan. 17, Medivation and Pfizer announced plans to discontinue development of Dimebon for all indications and to terminate their...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?